Q3 2017 Earnings Forecast for uniQure N.V. (QURE) Issued By Leerink Swann
uniQure N.V. (NASDAQ:QURE) – Leerink Swann lifted their Q3 2017 earnings estimates for uniQure N.V. in a report issued on Wednesday. Leerink Swann analyst J. Schwartz now forecasts that the biotechnology company will earn ($0.84) per share for the quarter, up from their previous estimate of ($0.88). Leerink Swann also issued estimates for uniQure N.V.’s Q4 2017 earnings at ($0.86) EPS, FY2017 earnings at ($3.34) EPS and FY2018 earnings at ($2.71) EPS.
A number of other research analysts also recently commented on the company. Chardan Capital set a $13.00 price objective on uniQure N.V. and gave the stock a “buy” rating in a research note on Sunday, July 23rd. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $17.00 price objective on shares of uniQure N.V. in a research note on Friday, June 30th. ValuEngine downgraded uniQure N.V. from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Cowen and Company restated a “buy” rating on shares of uniQure N.V. in a research note on Wednesday, May 24th. Finally, Zacks Investment Research downgraded uniQure N.V. from a “buy” rating to a “sell” rating in a research note on Wednesday, May 17th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $14.61.
ILLEGAL ACTIVITY WARNING: “Q3 2017 Earnings Forecast for uniQure N.V. (QURE) Issued By Leerink Swann” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/q3-2017-earnings-forecast-for-uniqure-n-v-qure-issued-by-leerink-swann.html.
Shares of uniQure N.V. (QURE) opened at 8.35 on Friday. uniQure N.V. has a one year low of $4.72 and a one year high of $9.72. The company’s 50 day moving average price is $7.23 and its 200 day moving average price is $6.06. The firm’s market capitalization is $213.43 million.
uniQure N.V. (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. uniQure N.V. had a negative return on equity of 135.97% and a negative net margin of 203.99%. The company had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million.
In other news, insider Harald Petry sold 49,300 shares of the stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $6.02, for a total value of $296,786.00. Following the completion of the transaction, the insider now owns 27,753 shares of the company’s stock, valued at $167,073.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last three months, insiders sold 173,460 shares of company stock valued at $1,042,986. Company insiders own 0.64% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. FMR LLC boosted its position in uniQure N.V. by 27.5% in the first quarter. FMR LLC now owns 1,498,463 shares of the biotechnology company’s stock valued at $8,661,000 after buying an additional 323,345 shares during the last quarter. P.A.W. Capital Corp acquired a new position in uniQure N.V. during the first quarter valued at about $867,000. Renaissance Technologies LLC boosted its position in uniQure N.V. by 48.8% in the first quarter. Renaissance Technologies LLC now owns 374,000 shares of the biotechnology company’s stock valued at $2,162,000 after buying an additional 122,700 shares during the last quarter. Paloma Partners Management Co boosted its position in uniQure N.V. by 717.7% in the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock valued at $491,000 after buying an additional 74,605 shares during the last quarter. Finally, Morgan Stanley boosted its position in uniQure N.V. by 14.9% in the first quarter. Morgan Stanley now owns 565,760 shares of the biotechnology company’s stock valued at $3,271,000 after buying an additional 73,418 shares during the last quarter. 30.22% of the stock is owned by institutional investors.
uniQure N.V. Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.